Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies

Epidermal growth factor receptor (EGFR) G724S mutation represents a resistance mechanism to first- and third-generation EGFR tyrosine kinase inhibitors. Limited data are available regarding the efficacy of afatinib in patients with non-small cell lung cancer (NSCLC) harboring G724S mutation, particu...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortiula, Francesco, Pelizzari, Giacomo, Corvaja, Carla, De Maglio, Giovanna, Fasola, Gianpiero
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481291/
https://www.ncbi.nlm.nih.gov/pubmed/35979997
http://dx.doi.org/10.1097/CAD.0000000000001321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481291/
https://www.ncbi.nlm.nih.gov/pubmed/35979997
http://dx.doi.org/10.1097/CAD.0000000000001321

Ejemplares similares